4 Einträge von 11 mit specialty rviii
www.cslbehring.ch
Datum der Indexierung 05.05.2021 02:08:20
erkannte Namen Alex Gertsch | Gérard Jenni | Amir Abrashi | Georg Ptak | Jérôme Gremaud | Bill Mezzanotte | Gene Therapy | Nat Rev | Tim Frei | Lia Huwiler |
weitere Namen in www.cslbehring.ch 11
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=AFE5B4AC5CAAF019462A6FA5337D981C7508AAE6
Kombination Keywords promise research | driven therapy | with fluad | cidp cell | phase japan | anti data | transplant market | hizentra study | privigen products | clinical patients |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty, Transplant, CSL112 Bill Campbell • Summary Bill Mezzanotte • Q&A | Driven by Our Promise™4 | Driven by Our Promise™4 Introduction and Highlights Professor Andrew Cuthbertson AO Chief Scientific Officer | Driven by Our Promise™5 | Driven by rVIII CSL312 Anti-FXIIa Mavri GM-CSFR- AZ* pdFVIII Ruide AFSTYLA® Discovery Projects CSL334 IL-13R* ASLAN CSL324 Anti-G-CSF Clinical Applications CSL311 Anti-BC CSL346 Anti-VEGF-B CSL112 apo-AI P. gingivalis/POD* OH-CRC Core Capab
Text Inhalt Text aus URL
Log Metriken 446265
erkannte Namen Alex Gertsch | Gérard Jenni | Amir Abrashi | Georg Ptak | Jérôme Gremaud | Bill Mezzanotte | Gene Therapy | Nat Rev | Tim Frei | Lia Huwiler |
weitere Namen in www.cslbehring.ch 11
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=en-us&hash=AFE5B4AC5CAAF019462A6FA5337D981C7508AAE6
Kombination Keywords promise research | driven therapy | with fluad | cidp cell | phase japan | anti data | transplant market | hizentra study | privigen products | clinical patients |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty, Transplant, CSL112 Bill Campbell • Summary Bill Mezzanotte • Q&A | Driven by Our Promise™4 | Driven by Our Promise™4 Introduction and Highlights Professor Andrew Cuthbertson AO Chief Scientific Officer | Driven by Our Promise™5 | Driven by rVIII CSL312 Anti-FXIIa Mavri GM-CSFR- AZ* pdFVIII Ruide AFSTYLA® Discovery Projects CSL334 IL-13R* ASLAN CSL324 Anti-G-CSF Clinical Applications CSL311 Anti-BC CSL346 Anti-VEGF-B CSL112 apo-AI P. gingivalis/POD* OH-CRC Core Capab
Text Inhalt Text aus URL
Log Metriken 446265
www.cslbehring.ch
Datum der Indexierung 05.05.2021 05:17:58
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=de-de&hash=0F4B700003E3B443708B55647A1D3C9F1AF9CDD4
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A Break • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines • CS rVIII-SC Voncento® EU Novel Plasma Proteins Influenza Vaccine Specialty Products Haemophilia Immunoglobulins Hizentra® CIDP Discovery Projects CSL324 G-CSFR CSL346 VEGFB CSL112 reconstituted HDL Partnered Vaccine Programs* P. ging
Text Inhalt Text aus URL
Log Metriken 446029
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=de-de&hash=0F4B700003E3B443708B55647A1D3C9F1AF9CDD4
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A Break • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines • CS rVIII-SC Voncento® EU Novel Plasma Proteins Influenza Vaccine Specialty Products Haemophilia Immunoglobulins Hizentra® CIDP Discovery Projects CSL324 G-CSFR CSL346 VEGFB CSL112 reconstituted HDL Partnered Vaccine Programs* P. ging
Text Inhalt Text aus URL
Log Metriken 446029
www.cslbehring.ch
Datum der Indexierung 25.04.2021 00:31:15
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A - Break - • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines rVIII-SC Ig Formulations Influenza Vaccine Specialty Products Haemophilia Immunoglobulins HIZENTRA® CIDP Discovery Projects CSL324 G-CSFR CSL346 VEGFB CSL112 reconstituted HDL Partnered Vaccine Programs* P. gingivalis/POD OH-CRC C
Text Inhalt Text aus URL
Log Metriken 563122
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A - Break - • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Breakthrough Medicines rVIII-SC Ig Formulations Influenza Vaccine Specialty Products Haemophilia Immunoglobulins HIZENTRA® CIDP Discovery Projects CSL324 G-CSFR CSL346 VEGFB CSL112 reconstituted HDL Partnered Vaccine Programs* P. gingivalis/POD OH-CRC C
Text Inhalt Text aus URL
Log Metriken 563122
www.cslbehring.ch
Datum der Indexierung 05.05.2021 04:36:59
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=494FDD9185B1042615BEEBFB38FFDCB1D72C821B
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summ rVIII CSL689 rVIIa-FP Congen Def CSL689 rVIIa-FP Inhibitors AFSTYLA ® Europe IDELVION ® US, EU, Japan Rec Coagulation Factors CSL334 IL-13R* ASLAN CSL640 rIX-FP subct Mavri GM-CSFR-AZ* AFLURIA® QIV 5-17 US, AUS AFTSYLA ® US P. gin
Text Inhalt Text aus URL
Log Metriken 446193
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=494FDD9185B1042615BEEBFB38FFDCB1D72C821B
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summ rVIII CSL689 rVIIa-FP Congen Def CSL689 rVIIa-FP Inhibitors AFSTYLA ® Europe IDELVION ® US, EU, Japan Rec Coagulation Factors CSL334 IL-13R* ASLAN CSL640 rIX-FP subct Mavri GM-CSFR-AZ* AFLURIA® QIV 5-17 US, AUS AFTSYLA ® US P. gin
Text Inhalt Text aus URL
Log Metriken 446193